Table 1 Baseline characteristics of patients.

Age, years

36.4 ± 10.4

39.5 ± 10.3

0.316

Male gender, n (%)

6 (28.6%)

7 (26.9%)

0.900

Disease duration, month

33.5 ± 32.3

39.4 ± 46.6

0.625

T3, ng/mL

1.04 ± 0.31

1.11 ± 0.37

0.474

Free T4, ng/dL

1.02 ± 0.19

1.13 ± 0.25

0.108

TSH, μIU/mL

2.13 ± 4.09

1.49 ± 3.56

0.570

TRAb, IU/L

6.32 ± 8.28

11.70 ± 13.87

0.140

TSI, %

289.0 ± 139.8

462.3 ± 171.2

0.003

Thyroid function status, n (%)

0.915

  Euthyroidism

11 (52.4%)

12 (46.2%)

  Subclinical hypothyroidism

2 (9.5%)

2 (7.7%)

  Subclinical hyperthyroidism

6 (28.6%)

10 (38.5%)

  Overt hyperthyroidism

2 (9.5%)

2 (7.7%)

Methimazole dose, mg

8.6 ± 5.1

11.8 ± 7.1

0.090

Antithyroid drug administration, n (%)

19 (90.5%)

24 (92.3%)

0.610

Levothyroxine dose, mcg

40.5 ± 47.1

52.9 ± 43.8

0.355

Levothyroixne administration, n (%)

11 (52.4%)

18 (69.2%)

0.237

CAS

  0

14 (53.8%)

  1

3 (11.5%)

  2

3 (11.5%)

  3

3 (11.5%)

  4

1 (3.8%)

Proptosis, mm

18.6 ± 2.6

NOSPECS

2.7 ± 1.6

Previous treatment for GO

  Glucocorticoid

11 (42.3%)

  Radiation therapy

3 (11.5%)